Titre : bêta-Alanine

bêta-Alanine : Questions médicales fréquentes

Termes MeSH sélectionnés :

Microphysiological Systems
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "bêta-Alanine : Questions médicales les plus fréquentes", "headline": "bêta-Alanine : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les bêta-Alanine : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-06-16", "dateModified": "2025-03-13", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "bêta-Alanine" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Alanine", "url": "https://questionsmedicales.fr/mesh/D000409", "about": { "@type": "MedicalCondition", "name": "Alanine", "code": { "@type": "MedicalCode", "code": "D000409", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.125.042" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Acide pantothénique", "alternateName": "Pantothenic Acid", "url": "https://questionsmedicales.fr/mesh/D010205", "about": { "@type": "MedicalCondition", "name": "Acide pantothénique", "code": { "@type": "MedicalCode", "code": "D010205", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.125.042.070.500" } } } ], "about": { "@type": "MedicalCondition", "name": "bêta-Alanine", "alternateName": "beta-Alanine", "code": { "@type": "MedicalCode", "code": "D015091", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Bryan Saunders", "url": "https://questionsmedicales.fr/author/Bryan%20Saunders", "affiliation": { "@type": "Organization", "name": "Applied Physiology and Nutrition Research Group, Rheumatology Division, Faculdade de Medicina FMUSP, School of Physical Education and Sport, University of São Paulo, São Paulo, Brazil." } }, { "@type": "Person", "name": "Eimear Dolan", "url": "https://questionsmedicales.fr/author/Eimear%20Dolan", "affiliation": { "@type": "Organization", "name": "Applied Physiology and Nutrition Research Group, Rheumatology Division, Faculdade de Medicina FMUSP, School of Physical Education and Sport, University of São Paulo, São Paulo, Brazil." } }, { "@type": "Person", "name": "Bruno Gualano", "url": "https://questionsmedicales.fr/author/Bruno%20Gualano", "affiliation": { "@type": "Organization", "name": "Applied Physiology and Nutrition Research Group, School of Physical Education and Sport; Rheumatology Division; Faculdade de Medicina FMUSP, Universidade de São Paulo, São Paulo, SP, BR, University of São Paulo, Brazil." } }, { "@type": "Person", "name": "Marcelo Papoti", "url": "https://questionsmedicales.fr/author/Marcelo%20Papoti", "affiliation": { "@type": "Organization", "name": "University of São Paulo, Medicine University of Ribeirão Preto (FMRP-USP), Ribeirão Preto, São Paulo, Brazil." } }, { "@type": "Person", "name": "Craig Sale", "url": "https://questionsmedicales.fr/author/Craig%20Sale", "affiliation": { "@type": "Organization", "name": "Musculoskeletal Physiology Research Group, Sport, Health and Performance Enhancement Research Centre, Nottingham Trent University, United Kingdom." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Surfactant-Dependent Partitioning of Organics in Aqueous-Organic Reaction Systems.", "datePublished": "2024-05-16", "url": "https://questionsmedicales.fr/article/38752624", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1021/acs.joc.4c00613" } }, { "@type": "ScholarlyArticle", "name": "Utility of ultrasound-based scoring system in post-pyeloplasty recovery.", "datePublished": "2024-05-16", "url": "https://questionsmedicales.fr/article/38753201", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s00383-024-05703-2" } }, { "@type": "ScholarlyArticle", "name": "Droplet Energy Harvesting System Based on Total-Current Nanogenerator.", "datePublished": "2024-05-15", "url": "https://questionsmedicales.fr/article/38749766", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1021/acsami.4c02607" } }, { "@type": "ScholarlyArticle", "name": "Can the Dose of Belimumab be Reduced in Patients with Systemic Lupus Erythematosus?", "datePublished": "2024-05-13", "url": "https://questionsmedicales.fr/article/38741198", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1093/rheumatology/keae270" } }, { "@type": "ScholarlyArticle", "name": "Impact of a health-system specialty pharmacy on time to upadacitinib initiation.", "datePublished": "2024-05-13", "url": "https://questionsmedicales.fr/article/38738829", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1093/ajhp/zxae123" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides aminés, peptides et protéines", "item": "https://questionsmedicales.fr/mesh/D000602" }, { "@type": "ListItem", "position": 3, "name": "Acides aminés", "item": "https://questionsmedicales.fr/mesh/D000596" }, { "@type": "ListItem", "position": 4, "name": "Alanine", "item": "https://questionsmedicales.fr/mesh/D000409" }, { "@type": "ListItem", "position": 5, "name": "bêta-Alanine", "item": "https://questionsmedicales.fr/mesh/D015091" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : bêta-Alanine - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur bêta-Alanine", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-09", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur bêta-Alanine", "description": "Comment diagnostiquer une carence en bêta-alanine ?\nQuels tests peuvent évaluer les niveaux de bêta-alanine ?", "url": "https://questionsmedicales.fr/mesh/D015091?mesh_terms=Microphysiological+Systems&page=1000#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur bêta-Alanine", "description": "Quels sont les symptômes d'une supplémentation excessive en bêta-alanine ?\nLa bêta-alanine cause-t-elle des effets secondaires ?", "url": "https://questionsmedicales.fr/mesh/D015091?mesh_terms=Microphysiological+Systems&page=1000#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur bêta-Alanine", "description": "Comment prévenir une carence en bêta-alanine ?\nLes sportifs doivent-ils se supplémenter en bêta-alanine ?", "url": "https://questionsmedicales.fr/mesh/D015091?mesh_terms=Microphysiological+Systems&page=1000#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur bêta-Alanine", "description": "La bêta-alanine est-elle utilisée pour traiter des maladies ?\nComment la bêta-alanine améliore-t-elle la performance ?", "url": "https://questionsmedicales.fr/mesh/D015091?mesh_terms=Microphysiological+Systems&page=1000#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur bêta-Alanine", "description": "Quelles complications peuvent survenir avec une surconsommation ?\nLa bêta-alanine peut-elle interagir avec d'autres médicaments ?", "url": "https://questionsmedicales.fr/mesh/D015091?mesh_terms=Microphysiological+Systems&page=1000#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur bêta-Alanine", "description": "Qui est à risque de carence en bêta-alanine ?\nLes athlètes d'endurance ont-ils besoin de plus de bêta-alanine ?", "url": "https://questionsmedicales.fr/mesh/D015091?mesh_terms=Microphysiological+Systems&page=1000#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une carence en bêta-alanine ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Il n'existe pas de test spécifique; une évaluation des symptômes et des apports alimentaires est nécessaire." } }, { "@type": "Question", "name": "Quels tests peuvent évaluer les niveaux de bêta-alanine ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des analyses sanguines peuvent mesurer les niveaux d'acides aminés, y compris la bêta-alanine." } }, { "@type": "Question", "name": "Quels sont les symptômes d'une supplémentation excessive en bêta-alanine ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Une supplémentation excessive peut provoquer des picotements, des démangeaisons ou des rougeurs." } }, { "@type": "Question", "name": "La bêta-alanine cause-t-elle des effets secondaires ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des effets secondaires comme des picotements peuvent survenir, mais ils sont généralement bénins." } }, { "@type": "Question", "name": "Comment prévenir une carence en bêta-alanine ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée incluant des sources de protéines peut prévenir une carence." } }, { "@type": "Question", "name": "Les sportifs doivent-ils se supplémenter en bêta-alanine ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les sportifs peuvent bénéficier d'une supplémentation pour améliorer leur endurance et performance." } }, { "@type": "Question", "name": "La bêta-alanine est-elle utilisée pour traiter des maladies ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Elle n'est pas un traitement médical, mais un complément pour améliorer la performance sportive." } }, { "@type": "Question", "name": "Comment la bêta-alanine améliore-t-elle la performance ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Elle augmente les niveaux de carnosine dans les muscles, retardant la fatigue lors d'exercices intenses." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec une surconsommation ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Une surconsommation peut entraîner des troubles gastro-intestinaux et des picotements." } }, { "@type": "Question", "name": "La bêta-alanine peut-elle interagir avec d'autres médicaments ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Des interactions sont possibles; il est conseillé de consulter un professionnel de santé." } }, { "@type": "Question", "name": "Qui est à risque de carence en bêta-alanine ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Les personnes ayant une alimentation pauvre en protéines ou végétalienne peuvent être à risque." } }, { "@type": "Question", "name": "Les athlètes d'endurance ont-ils besoin de plus de bêta-alanine ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils peuvent avoir besoin de plus de bêta-alanine pour améliorer leur performance et récupération." } } ] } ] }

Sources (10000 au total)

Utility of ultrasound-based scoring system in post-pyeloplasty recovery.

Differentiation of uretero-pelvic junction obstruction (UPJO) from non-obstructive dilatation (NOD) is a major challenge. The aim of this retrospective study is to determine whether pyeloplasty predic... Among patients with antenatally diagnosed hydronephrosis, those who were stable during post-natal follow-up were considered NOD. The UPJO group were the ones who worsened and underwent pyeloplasty bas... Among 137 patients included (R:L = 59:73; M:F 102:35), 96 were conservatively managed (NOD), while 41 patients (29%) needed pyeloplasty (UPJO). Mean PPS was 4.2 (1.2) in the NOD group and it was signi... A PPS cutoff value of 8 or above is associated with the presence of significant UPJO. PPS is also useful in the assessment of hydronephrosis recovery post-pyeloplasty. The limitation of PPS: it can on...

Can the Dose of Belimumab be Reduced in Patients with Systemic Lupus Erythematosus?

The aims of this study were to investigate the prevalence of dose reduction in patients with SLE treated with belimumab (BEL) in Spain, analyze treatment modalities, and determine impact on control of... Retrospective longitudinal and multicentre study of SLE patients treated with BEL. Data on disease activity, treatments and outcomes were recorded before and after reduction (6-12 months), and they we... A total of 324 patients were included. The dose was reduced in 29 patients (8.9%). The dosing interval was increased in 9 patients receiving subcutaneous BEL and in 6 patients receiving intravenous BE... Doses of BEL can be reduced with no relevant changes in disease activity-at least in the short term-in a significant percentage of patients, and most maintain the reduced dose. However, increased clin...

Impact of a health-system specialty pharmacy on time to upadacitinib initiation.

In an effort to expedite the publication of articles, AJHP is posting manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are post... Upadacitinib has been found to improve symptoms as early as day 1 in patients with inflammatory bowel disease. As a result, early and timely initiation of upadacitinib is paramount to prevent hospital... This was a single-center, retrospective study at the University of Chicago Medicine (UCM) Inflammatory Bowel Disease Center and included patients initiated on upadacitinib between March 1, 2022, and A... A total of 107 patients were initiated on upadacitinib during the study period (n = 18 through the UCM HSSP, n = 89 through an ESP). The median number of days to patient initiation was 3 days (interqu... This study validates the ability of HSSPs to initiate therapies earlier than ESPs with a particular focus on upadacitinib....

Clinical characteristics of systemic lupus erythematosus patients with adrenal hemorrhage.

Adrenal hemorrhage (AH) is a rare condition and severe cases can lead to acute adrenal insufficiency with potentially life-threatening consequences. AH can be caused by a variety of etiologic factors,... The aims of this study were to analyze and summarize the clinical characteristics of systemic lupus erythematosus patients with AH.... The clinical characteristics of 6 systemic lupus erythematosus patients complicated with AH admitted to Peking Union Medical College Hospital and Beijing Shijitan Hospital from May 2004 to April 2022 ... The diagnosis of AH was based on computed tomography (CT) findings. Two patients had bilateral lesions, and the other 4 patients had unilateral lesions. The symptoms of adrenal insufficiency were obse... In the proper clinical setting, having high clinical suspicion for AH, early diagnosis and timely management is crucial to avoid life-threatening adrenal insufficiency. Key Points • AH is a rare condi...

Use of a dedicated open transcarotid access system for neurovascular disease.

Transcarotid artery revascularization (TCAR) is an increasingly popular technique for the management of extracranial carotid stenosis. Its off-label use in the treatment of intracranial neurovascular ... We conducted a retrospective review of a prospectively maintained database of consecutive patients who underwent treatment of neurovascular disease at a single academic center using the ENROUTE Transc... Twenty patients were included in the study between September 2017 and March 2023. The following pathologies were treated: intracranial atherosclerotic disease (ICAD, nine patients), complex cervico-pe... An open transcarotid approach using a dedicated transcarotid system may offer a safe alternative access strategy for the endovascular treatment of complex neurovascular pathologies when a traditional ...